Fig. 1: Distinct histone PTMs in micronuclei.
From: Epigenetic dysregulation from chromosomal transit in micronuclei
a, Representative immunofluorescence images from three biological replicates of micronucleated MDA-MB-231 cells stained for DNA (blue) and histone post-translational modifications (PTMs; red). White outlined boxes show a magnified view of micronuclei. b, Percentage of primary nuclei (blue) and micronuclei with particular histone PTMs (red) from an immunofluorescence experiment using human MDA-MB-231 (top) and mouse 4T1 (bottom) cells. **P < 0.01, ***P < 0.001, ****P < 0.0001, two-sided t-test, n = 3 biological replicates; data represent mean ± s.d.; n.s., not significant. c, Percentage of micronuclei with particular histone PTMs from an immunofluorescence experiment in MDA-MB-231 cells treated with DMSO vehicle control or vorinostat (HDAC inhibitor, HDACi). Statistical details are the same as in b. d, Heat map of z-scores of the relative abundance of histone PTMs from histone mass spectrometry in isolated micronuclei and primary nuclei of mouse 4T1 cells; n = 3. e, Percentage of micronuclei with H3K27me3 and H3K27ac from immunofluorescence staining in human high-grade serous ovarian cancer (HGSOC) tumour samples; n = 16, statistical significance tested using two-sided paired t-test; p < 0.0001. f, Representative immunofluorescence images of 16 human HGSOC tumour samples stained for DNA (blue) and either H3K27me3 or H3K27ac (red). In a and f, arrows, micronuclei; scale bars, 2 µm.
